SG11201705215PA - Quinazoline derivatives used to treat hiv - Google Patents

Quinazoline derivatives used to treat hiv

Info

Publication number
SG11201705215PA
SG11201705215PA SG11201705215PA SG11201705215PA SG11201705215PA SG 11201705215P A SG11201705215P A SG 11201705215PA SG 11201705215P A SG11201705215P A SG 11201705215PA SG 11201705215P A SG11201705215P A SG 11201705215PA SG 11201705215P A SG11201705215P A SG 11201705215PA
Authority
SG
Singapore
Prior art keywords
derivatives used
quinazoline derivatives
treat hiv
hiv
treat
Prior art date
Application number
SG11201705215PA
Other languages
English (en)
Inventor
Petr Jansa
Petr Simon
Eric Lansdon
Yunfeng Eric Hu
Ondrej Baszczynski
Milan Dejmek
Richard L Mackman
Original Assignee
Gilead Sciences Inc
Inst Of Organic Chemistry And Biochemistry Of The As Cr V V I
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Inst Of Organic Chemistry And Biochemistry Of The As Cr V V I filed Critical Gilead Sciences Inc
Publication of SG11201705215PA publication Critical patent/SG11201705215PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201705215PA 2014-12-24 2015-12-23 Quinazoline derivatives used to treat hiv SG11201705215PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462096748P 2014-12-24 2014-12-24
PCT/US2015/000460 WO2016105564A1 (fr) 2014-12-24 2015-12-23 Dérivés de quinazoline utilisés pour traiter le vih

Publications (1)

Publication Number Publication Date
SG11201705215PA true SG11201705215PA (en) 2017-07-28

Family

ID=55305044

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202101143VA SG10202101143VA (en) 2014-12-24 2015-12-23 Quinazoline derivatives used to treat hiv
SG11201705215PA SG11201705215PA (en) 2014-12-24 2015-12-23 Quinazoline derivatives used to treat hiv

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202101143VA SG10202101143VA (en) 2014-12-24 2015-12-23 Quinazoline derivatives used to treat hiv

Country Status (41)

Country Link
US (5) US9730936B2 (fr)
EP (4) EP3237398B1 (fr)
JP (2) JP6367489B2 (fr)
KR (2) KR102288855B1 (fr)
CN (2) CN107278201B (fr)
AR (1) AR103252A1 (fr)
AU (1) AU2015371198B2 (fr)
BR (1) BR102015032361B1 (fr)
CA (1) CA2972021C (fr)
CL (1) CL2017001675A1 (fr)
CO (1) CO2017006214A2 (fr)
CR (1) CR20170281A (fr)
CU (1) CU20170089A7 (fr)
CY (1) CY1124726T1 (fr)
DK (1) DK3521282T3 (fr)
DO (1) DOP2017000151A (fr)
EA (2) EA035746B1 (fr)
EC (1) ECSP17039611A (fr)
ES (3) ES2715507T3 (fr)
HK (1) HK1244001B (fr)
HR (1) HRP20211543T1 (fr)
HU (1) HUE058296T2 (fr)
IL (2) IL253059B (fr)
LT (1) LT3521282T (fr)
MA (1) MA48448A (fr)
MD (1) MD4650B1 (fr)
MX (2) MX367574B (fr)
MY (1) MY189761A (fr)
NZ (1) NZ733174A (fr)
PE (1) PE20171306A1 (fr)
PH (1) PH12017501191B1 (fr)
PL (3) PL3237398T3 (fr)
PT (2) PT3237398T (fr)
SA (1) SA517381826B1 (fr)
SG (2) SG10202101143VA (fr)
SI (2) SI3237398T1 (fr)
SV (1) SV2017005471A (fr)
TR (1) TR201903672T4 (fr)
TW (3) TWI699355B (fr)
UA (1) UA117796C2 (fr)
WO (1) WO2016105564A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006738A1 (fr) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Composés pour traiter le vih
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
NZ733135A (en) 2014-12-24 2018-06-29 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
BR112017013440A2 (pt) 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de isoquinolina para o tratamento de hiv
HRP20211456T1 (hr) 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
MA42795B1 (fr) 2016-08-19 2019-08-30 Gilead Sciences Inc Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
KR102248165B1 (ko) 2017-12-07 2021-05-06 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
CN111836805B (zh) 2018-02-15 2023-07-14 吉利德科学公司 吡啶衍生物及其用于治疗hiv感染的用途
KR20230145536A (ko) 2018-02-16 2023-10-17 길리애드 사이언시즈, 인코포레이티드 레트로비리다에 바이러스 감염의 치료에 유용한 치료 화합물을 제조하기 위한 방법 및 중간체
CA3216031A1 (fr) 2018-07-16 2020-01-23 Gilead Sciences, Inc. Inhibiteurs de capsides pour le traitement du vih
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
WO2020214647A1 (fr) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Formes solides d'un inhibiteur de protéase du vih
KR20220106165A (ko) 2019-11-26 2022-07-28 길리애드 사이언시즈, 인코포레이티드 Hiv의 예방을 위한 캡시드 억제제
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
AU2021261519A1 (en) 2020-04-24 2022-12-15 Sumitomo Pharma Co., Ltd. 2-heteroarylaminoquinazolinone derivative
CA3181690A1 (fr) 2020-06-25 2021-12-30 Chienhung CHOU Inhibiteurs de capside pour le traitement du vih
EP4244396A1 (fr) 2020-11-11 2023-09-20 Gilead Sciences, Inc. Procédés d'identification des patients vih sensibles à la thérapie avec des anticorps visant le site de liaison cd4 de la gp120
TW202342447A (zh) 2021-12-03 2023-11-01 美商基利科學股份有限公司 用於ｈｉｖ病毒感染之治療性化合物
TW202337439A (zh) 2021-12-03 2023-10-01 美商基利科學股份有限公司 用於ｈｉｖ病毒感染之治療性化合物
WO2023102529A1 (fr) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Composés thérapeutiques pour l'infection par le virus du vih
TW202400172A (zh) 2022-04-06 2024-01-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20240034724A1 (en) 2022-07-01 2024-02-01 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2024044477A1 (fr) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Régime de dosage et de planification pour anticorps largement neutralisants
WO2024076915A1 (fr) 2022-10-04 2024-04-11 Gilead Sciences, Inc. Analogues de 4'-thionucléosides et leur utilisation pharmaceutique

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ197420A (en) 1980-07-01 1984-04-27 Ici Australia Ltd -(quinazolin-(2-or 4-)(oxy,ylthio or amino)phen(oxy or ylthio)alkanoic acid derivatives
JPH11209350A (ja) 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬
ATE339406T1 (de) 1999-09-23 2006-10-15 Astrazeneca Ab Chinazoline verbindungen als heilmittel
CA2386955A1 (fr) 1999-11-22 2001-05-31 Warner-Lambert Company Quinazolines et leur utilisation dans l'inhibition des enzymes kinase dependant de la cycline
GB0002032D0 (en) 2000-01-28 2000-03-22 Zeneca Ltd Chemical compounds
WO2002010136A1 (fr) 2000-08-02 2002-02-07 Celltech R & D Limited Derives d'isoquinoline-1-yl substitues en 3
MXPA03002410A (es) 2000-09-20 2003-06-19 Merck Patent Gmbh 4-amino-quinazolinas.
AU2003255482A1 (en) 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
CA2523083C (fr) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Analogues de phosphonate antiviraux
WO2004108711A1 (fr) 2003-06-05 2004-12-16 Astrazeneca Ab Derives pyrazinile quinazoline destines au traitement de tumeurs
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
PT1778251E (pt) 2004-07-27 2011-06-29 Gilead Sciences Inc Análogos de fosfonato de compostos inibidores de vih
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CA2577588C (fr) 2004-10-29 2013-09-10 Tibotec Pharmaceuticals Ltd. Derives de pyrimidine bicycliques inhibant le vih
KR20060079121A (ko) 2004-12-31 2006-07-05 에스케이케미칼주식회사 당뇨 및 비만 치료예방에 유효한 퀴나졸린 유도체
WO2006099301A2 (fr) 2005-03-10 2006-09-21 The Regents Of The University Of California Inhibiteurs de l'apoptose
JP5079500B2 (ja) 2005-04-28 2012-11-21 協和発酵キリン株式会社 ２−アミノキナゾリン誘導体
CN101213187B (zh) 2005-06-28 2012-06-06 塞诺菲-安万特股份有限公司 作为rho-激酶抑制剂的异喹啉衍生物
KR101373535B1 (ko) 2005-07-26 2014-03-12 사노피 Ｒｈｏ-키나제 억제제로서의 피페리디닐-치환된 이소퀴놀론유도체
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
CN103382216B (zh) 2006-01-27 2016-04-20 菲布罗根有限公司 使低氧诱导因子（hif）稳定的氰基异喹啉化合物
AR060358A1 (es) 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
WO2007125405A2 (fr) 2006-05-01 2007-11-08 Pfizer Products Inc. Composés hétérocycliques 2-amino-substitués à cycles fusionnés
CA2658462C (fr) 2006-07-20 2011-09-27 Amgen Inc. Composes de pyridone substitues et procedes d'utilisation
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
JPWO2008050808A1 (ja) 2006-10-24 2010-02-25 協和発酵キリン株式会社 ２−アミノキナゾリン誘導体
MX2009005825A (es) 2006-12-27 2009-06-16 Sanofi Aventis Derivados de isoquinolina e isoquinolinona sustituidos en calidad de inhibidores de rho-quinasa.
JP5405314B2 (ja) 2006-12-27 2014-02-05 サノフイ シクロアルキルアミン置換イソキノロン誘導体
ATE505458T1 (de) 2006-12-27 2011-04-15 Sanofi Aventis Cycloalkylaminsubstituierte isochinolon- und isochinolinonderivate
US20090004185A1 (en) 2007-01-11 2009-01-01 Wyeth Amino-substituted quinazoline derivatives as inhibitors of beta-catenin/tcf-4 pathway and cancer treatment agents
BRPI0809913A2 (pt) 2007-04-06 2014-10-07 Novartis Ag Derivados de 2,6-naftiridina como moduladores da proteína quinase
WO2008157500A1 (fr) 2007-06-17 2008-12-24 Kalypsys, Inc. Modulateurs du récepteur cannabinoïde à base d'aminoquinazoline pour le traitement de maladies
EA201200631A1 (ru) 2007-11-16 2012-11-30 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
KR20100134693A (ko) 2008-04-23 2010-12-23 교와 핫꼬 기린 가부시키가이샤 2-아미노퀴나졸린 유도체
WO2009155121A2 (fr) 2008-05-30 2009-12-23 Amgen Inc. Inhibiteurs de la pi3 kinase
GB0812969D0 (en) 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
JP5335082B2 (ja) 2008-08-15 2013-11-06 ビーエーエスエフ ソシエタス・ヨーロピア ナノスケールの有機固体粒子の製造方法
TWI432436B (zh) 2008-12-09 2014-04-01 Gilead Sciences Inc 類鐸受體的調節劑
MA32968B1 (fr) 2008-12-29 2012-01-02 Fovea Pharmaceuticals Composes quinazoline substitues
ES2493916T3 (es) 2009-04-07 2014-09-12 Infinity Pharmaceuticals, Inc. Inhibidores de hidrolasa de amida de ácidos grasos
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
WO2011035416A1 (fr) 2009-09-25 2011-03-31 Aegera Therapeutics Inc. Composés modulateurs de la hsp90, compositions, procédés et utilisations correspondants
US20130165489A1 (en) 2010-05-03 2013-06-27 The Trustees Of The University Of Pennsylvania Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
TW201204723A (en) 2010-06-22 2012-02-01 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application
US9102617B2 (en) 2010-06-25 2015-08-11 Rutgers, The State University Of New Jersey Antimicrobial agents
MA34397B1 (fr) 2010-07-02 2013-07-03 Gilead Sciences Inc Dérivés d'acide napht-2-ylacétique dans le traitement du sida
PE20130525A1 (es) 2010-07-02 2013-05-05 Gilead Sciences Inc Derivados de acido 2 quinolinil acetico como compuestos antivirales frente a vih
WO2012044090A2 (fr) 2010-09-29 2012-04-05 크리스탈지노믹스(주) Nouveau composé d'aminoquinazoline possédant une action inhibitrice de la protéine kinase
KR20120038060A (ko) 2010-10-13 2012-04-23 롬엔드하스전자재료코리아유한회사 신규한 유기 전자재료용 화합물 및 이를 포함하는 유기 전계 발광 소자
BR112013013790A2 (pt) 2010-12-17 2016-09-13 Hoffmann La Roche compostos heterocíclos nitrogenosos 6,6-fundidos substituídos e usos dos mesmos
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
CA2833377C (fr) 2011-04-21 2019-02-12 Gilead Sciences, Inc. Composes benzothiazoles et leur utilisation pharmaceutique
WO2013006738A1 (fr) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Composés pour traiter le vih
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
US9399645B2 (en) 2011-12-20 2016-07-26 Boehringer Ingelheim International Gmbh Inhibitors of HIV replication
PE20141558A1 (es) 2012-04-20 2014-11-06 Gilead Sciences Inc Derivados de acido benzotiazol-6-il acetico y su uso para tratar una infeccion por vih
MD4841B1 (ro) 2012-12-21 2023-01-31 Gilead Sciences, Inc. Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
RU2015131006A (ru) 2012-12-27 2017-01-30 Джапан Тобакко Инк. ЗАМЕЩЕННОЕ ПРОИЗВОДНОЕ СПИРОПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В МЕДИЦИНЕ В КАЧЕСТВЕ ИНГИБИТОРА ИНТЕГРАЗЫ ВИРУСА ИММУНОДЕФИЦИТА ЧЕЛОВЕКА (ВИЧ)
EP2769722A1 (fr) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Composés utilisés pour inhiber un assemblage de capside du VIH
EP2769723A1 (fr) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Composés utilisés pour inhiber un assemblage de capside du VIH
US9914709B2 (en) 2013-06-21 2018-03-13 Yale University Compositions and methods of treating HIV-1 infections using same
NZ733135A (en) 2014-12-24 2018-06-29 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
BR112017013440A2 (pt) 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de isoquinolina para o tratamento de hiv
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物

Also Published As

Publication number Publication date
EP3960735C0 (fr) 2023-09-13
TW202237569A (zh) 2022-10-01
WO2016105564A1 (fr) 2016-06-30
US20170354656A1 (en) 2017-12-14
PH12017501191A1 (en) 2018-03-05
PL3960735T3 (pl) 2024-03-18
AU2015371198B2 (en) 2018-09-27
AR103252A1 (es) 2017-04-26
IL253059B (en) 2019-10-31
CN107278201A (zh) 2017-10-20
CR20170281A (es) 2017-11-08
US20190134035A1 (en) 2019-05-09
KR102288855B1 (ko) 2021-08-11
CY1124726T1 (el) 2022-07-22
EA201791256A1 (ru) 2018-04-30
MX2017008521A (es) 2018-03-01
US10548898B2 (en) 2020-02-04
TW201636328A (zh) 2016-10-16
DOP2017000151A (es) 2017-09-15
SI3521282T1 (sl) 2021-11-30
WO2016105564A8 (fr) 2016-10-06
EP3237398A1 (fr) 2017-11-01
PT3237398T (pt) 2019-03-06
JP6367489B2 (ja) 2018-08-01
EA035746B1 (ru) 2020-08-05
EP4302830A2 (fr) 2024-01-10
SV2017005471A (es) 2018-01-18
US20160250215A1 (en) 2016-09-01
PT3521282T (pt) 2021-11-29
TWI770552B (zh) 2022-07-11
NZ733174A (en) 2018-12-21
US11304948B2 (en) 2022-04-19
MA48448A (fr) 2021-04-28
BR102015032361A8 (pt) 2021-08-31
CN111574464A (zh) 2020-08-25
JP2018168181A (ja) 2018-11-01
TWI699355B (zh) 2020-07-21
EP3521282A1 (fr) 2019-08-07
MY189761A (en) 2022-03-03
BR102015032361B1 (pt) 2021-12-21
KR102049476B1 (ko) 2019-11-28
ES2964395T3 (es) 2024-04-05
ECSP17039611A (es) 2017-07-31
ES2715507T3 (es) 2019-06-04
CU20170089A7 (es) 2017-11-07
IL269635B (en) 2021-04-29
UA117796C2 (uk) 2018-09-25
PL3237398T3 (pl) 2019-05-31
MD20170070A2 (ro) 2017-12-31
SI3237398T1 (sl) 2019-04-30
KR20170131351A (ko) 2017-11-29
SA517381826B1 (ar) 2021-10-21
TR201903672T4 (tr) 2019-04-22
HUE058296T2 (hu) 2022-07-28
MD4650B1 (ro) 2019-09-30
EA202091115A1 (ru) 2021-01-29
US10206926B2 (en) 2019-02-19
EP4302830A3 (fr) 2024-03-13
IL269635A (en) 2019-11-28
CA2972021C (fr) 2020-04-28
IL253059A0 (en) 2017-08-31
CO2017006214A2 (es) 2017-10-20
PL3521282T3 (pl) 2022-01-03
CL2017001675A1 (es) 2018-05-11
ES2900810T3 (es) 2022-03-18
US9730936B2 (en) 2017-08-15
JP2018500358A (ja) 2018-01-11
KR20190133068A (ko) 2019-11-29
EP3237398B1 (fr) 2018-12-19
HK1244001B (zh) 2020-01-10
PE20171306A1 (es) 2017-09-05
HRP20211543T1 (hr) 2022-01-07
SG10202101143VA (en) 2021-03-30
AU2015371198A1 (en) 2017-07-13
BR102015032361A2 (pt) 2016-07-05
MX2019009932A (es) 2019-10-02
CA2972021A1 (fr) 2016-06-30
US20200360383A1 (en) 2020-11-19
CN107278201B (zh) 2020-05-19
MX367574B (es) 2019-08-27
PH12017501191B1 (en) 2018-03-05
EP3960735A1 (fr) 2022-03-02
EP3960735B1 (fr) 2023-09-13
US20230043136A1 (en) 2023-02-09
DK3521282T3 (da) 2021-09-27
EP3521282B1 (fr) 2021-08-25
TW202106667A (zh) 2021-02-16
LT3521282T (lt) 2021-11-25

Similar Documents

Publication Publication Date Title
IL269635B (en) History of conazole used to treat hiv
HK1246776A1 (zh) 用於hiv治療的異喹啉化合物
HK1245092A1 (zh) 膏藥
HK1257272A1 (zh) 治療hiv的工具
SG11201606199SA (en) Ketoprofen-containing poultice
HUE050165T2 (hu) Etilén-glikolok MMF származékai
GB2522473B (en) Improvements to windposts
GB2522039B (en) I-beam
GB201401124D0 (en) Anti-inflammatory solution
AU5297P (en) FlatstenoGL Grevillea stenomera
AU5296P (en) LowstenoGL Grevillea stenomera
GB2520781B (en) Improvements to hydro-turbines
AU2014903428A0 (en) Treatment of HIV
GB201414186D0 (en) Secure tip
GB201421232D0 (en) Retro-reflector
GB201405489D0 (en) Able to go
GB201409013D0 (en) My site
GB201409028D0 (en) Easy see mouse
GB201406790D0 (en) Laser treatment
GB201400235D0 (en) Treatment